Exelixis claims a series of RAF kinase inhibitors based on a 3-oxo-2,3-dihydro-1H-isoindol-1-yl core structure. Both the chemical matter and the biochemical target appear to be new for Exelixis, and many examples have IC(50) values < 100 nM. These compounds are claimed to have the potential to treat diseases that are associated with uncontrolled, abnormal and/or unwanted cellular activities such as cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/13543776.16.7.1031 | DOI Listing |
Publication Analysis
Top Keywords
raf modulators
4
modulators methods
4
methods exelixis
4
exelixis claims
4
claims series
4
series raf
4
raf kinase
4
kinase inhibitors
4
inhibitors based
4
based 3-oxo-23-dihydro-1h-isoindol-1-yl
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!